Anthem Biosciences Q3 FY26 earnings call
In brief
The recording, the transcript and our read of the call usually follow within a few days. Nothing beyond the invite is filed yet.
The numbers
The quarter, Q3 FY26
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹423 cr | — | −23.1% | |
| EBITDA (excl. other income) | ₹132 cr | — | −39.5% | 31.2% |
| Net profit | ₹0 cr | — | — | 0% |
| EPS (₹) | ₹1.65 | — | −46.6% |
From the company's filed results for the quarter ended 31 Dec 2025 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
Guidance
Guided on earlier calls, and what was filed
| What | For | Guided | Filed |
|---|---|---|---|
| EBITDA margin | FY26 | at least 38% (on the Q1 FY26 call) | 38.1%, within the range |
| EBITDA margin (normalized, excl FX) | FY26 | 36–37% (on the Q2 FY26 call) | 38.1%, above the range |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
Transcript
No transcript is filed yet. Companies usually file one within a week of the call.
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Thu 5 Feb 2026 | ₹635.00 | +4.91% | −0.52% |
| 5 sessions Wed 11 Feb 2026 | ₹692.15 | +14.35% | +0.69% |
| 20 sessions Thu 5 Mar 2026 | ₹667.75 | +10.32% | −3.92% |
From the close of Wed 4 Feb 2026, ₹605.30: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.